{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T06:07:02Z","timestamp":1759385222695},"reference-count":15,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,3,20]]},"DOI":"10.7759\/cureus.56586","type":"journal-article","created":{"date-parts":[[2024,3,20]],"date-time":"2024-03-20T23:22:55Z","timestamp":1710976975000},"source":"Crossref","is-referenced-by-count":1,"title":["Epstein-Barr-Virus-Related Lymphoproliferative Disorder in a Patient With Primary Myelofibrosis: A Case Report and Literature Review"],"prefix":"10.7759","author":[{"given":"Seigi","family":"Oshima","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shojiro","family":"Inano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Toshiyuki","family":"Kitano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2022017423","article-title":"Myelofibrosis","volume":"141","author":"Passamonti F","year":"2023","unstructured":"Passamonti F, Mora B. Myelofibrosis. Blood. 2023, 141:1954-70. 10.1182\/blood.2022017423","journal-title":"Blood"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2022017578","article-title":"Genetic basis and molecular profiling in myeloproliferative neoplasms","volume":"141","author":"Luque Paz D","year":"2023","unstructured":"Luque Paz D, Kralovics R, Skoda RC. Genetic basis and molecular profiling in myeloproliferative neoplasms. Blood. 2023, 141:1909-21. 10.1182\/blood.2022017578","journal-title":"Blood"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1110557","article-title":"A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis","volume":"366","author":"Verstovsek S","year":"2012","unstructured":"Verstovsek S, Mesa RA, Gotlib J, et al.. A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis. N Engl J Med. 2012, 366:799-807. 10.1056\/NEJMoa1110557","journal-title":"N Engl J Med"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2017-10-810739","article-title":"Aggressive B-cell lymphomas in patients with myelofibrosis receiving JAK1\/2 inhibitor therapy","volume":"132","author":"Porpaczy E","year":"2018","unstructured":"Porpaczy E, Tripolt S, Hoelbl-Kovacic A, et al.. Aggressive B-cell lymphomas in patients with myelofibrosis receiving JAK1\/2 inhibitor therapy. Blood. 2018, 132:694-706. 10.1182\/blood-2017-10-810739","journal-title":"Blood"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.25489","article-title":"Ruxolitinib treatment and risk of B-cell lymphomas in myeloproliferative neoplasms","volume":"94","author":"Rumi E","year":"2019","unstructured":"Rumi E, Zibellini S, Boveri E, et al.. Ruxolitinib treatment and risk of B-cell lymphomas in myeloproliferative neoplasms. Am J Hematol. 2019, 94:E185-8. 10.1002\/ajh.25489","journal-title":"Am J Hematol"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2019-01-897637","article-title":"Characteristics of patients with myeloproliferative neoplasms with lymphoma, with or without JAK inhibitor therapy","volume":"133","author":"Pemmaraju N","year":"2019","unstructured":"Pemmaraju N, Kantarjian H, Nastoupil L, et al.. Characteristics of patients with myeloproliferative neoplasms with lymphoma, with or without JAK inhibitor therapy. Blood. 2019, 133:2348-51. 10.1182\/blood-2019-01-897637","journal-title":"Blood"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1056","article-title":"Epstein-Barr virus infection","volume":"17","author":"Cohen JI","year":"2000","unstructured":"Cohen JI. Epstein-Barr virus infection. N Engl J Med. 2000, 17:481-92. 10.1056","journal-title":"N Engl J Med"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1016\/s1074-7613(00)80622-6","article-title":"EBV persistence in memory B cells in vivo","volume":"9","author":"Babcock GJ","year":"1998","unstructured":"Babcock GJ, Decker LL, Volk M, Thorley-Lawson DA. EBV persistence in memory B cells in vivo. Immunity. 1998, 9:395-404. 10.1016\/s1074-7613(00)80622-6","journal-title":"Immunity"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2020005466","article-title":"EBV+ lymphoproliferative diseases: opportunities for leveraging EBV as a therapeutic target","volume":"139","author":"Toner K","year":"2022","unstructured":"Toner K, Bollard CM. EBV+ lymphoproliferative diseases: opportunities for leveraging EBV as a therapeutic target. Blood. 2022, 139:983-94. 10.1182\/blood.2020005466","journal-title":"Blood"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2019.01186","article-title":"Mechanisms Underlying the Anti-inflammatory and Immunosuppressive Activity of Ruxolitinib","volume":"9","author":"Elli EM","year":"2019","unstructured":"Elli EM, Barat\u00e8 C, Mendicino F, Palandri F, Palumbo GA. Mechanisms Underlying the Anti-inflammatory and Immunosuppressive Activity of Ruxolitinib. Front Oncol. 2019, 9:1186. 10.3389\/fonc.2019.01186","journal-title":"Front Oncol"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1016\/j.leukres.2022.107005","article-title":"Ruxolitinib-induced reactivation of cytomegalovirus and Epstein-Barr virus in graft-versus-host disease","volume":"125","author":"Lebon D","year":"2023","unstructured":"Lebon D, Dujardin A, Caulier A, et al.. Ruxolitinib-induced reactivation of cytomegalovirus and Epstein-Barr virus in graft-versus-host disease. Leuk Res. 2023, 125:107005. 10.1016\/j.leukres.2022.107005","journal-title":"Leuk Res"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1177\/10668969221137525","article-title":"EBV-gastritis preceded the development of nasopharyngeal EBV (+) diffuse large B cell lymphoma in a patient with ruxolitinib-induced immunosuppression","volume":"31","author":"Puello Yocum B","year":"2023","unstructured":"Puello Yocum B, Mesa H, Maratt JK, Ermel AC, Manchanda N, Popnikolov N. EBV-gastritis preceded the development of nasopharyngeal EBV (+) diffuse large B cell lymphoma in a patient with ruxolitinib-induced immunosuppression. Int J Surg Pathol. 2023, 31:1340-6. 10.1177\/10668969221137525","journal-title":"Int J Surg Pathol"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1186\/s12878-015-0029-1","article-title":"Case-report: EBV driven lymphoproliferative disorder associated with ruxolitinib","volume":"15","author":"P\u00e1lmason R","year":"2015","unstructured":"P\u00e1lmason R, Lind\u00e9n O, Richter J. Case-report: EBV driven lymphoproliferative disorder associated with ruxolitinib. BMC Hematol. 2015, 15:10. 10.1186\/s12878-015-0029-1","journal-title":"BMC Hematol"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.5045\/br.2019.54.4.282","article-title":"EBV reactivation mimicking a lymphoproliferative disorder associated with ruxolitinib therapy for myelofibrosis","volume":"54","author":"Prem S","year":"2019","unstructured":"Prem S, Loach D, Lipton J, Kumar R, Gupta V. EBV reactivation mimicking a lymphoproliferative disorder associated with ruxolitinib therapy for myelofibrosis. Blood Res. 2019, 54:282-4. 10.5045\/br.2019.54.4.282","journal-title":"Blood Res"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.26026","article-title":"First case of classical Hodgkin-like EBV-positive lymphoproliferative disorder under ruxolitinib therapy","volume":"96","author":"Mouchel PL","year":"2021","unstructured":"Mouchel PL, Syrykh C, Laurent C, Tavitian S, Gauthier M. First case of classical Hodgkin-like EBV-positive lymphoproliferative disorder under ruxolitinib therapy. Am J Hematol. 2021, 96:755-6. 10.1002\/ajh.26026","journal-title":"Am J Hematol"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/229617-epstein-barr-virus-related-lymphoproliferative-disorder-in-a-patient-with-primary-myelofibrosis-a-case-report-and-literature-review","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,3,20]],"date-time":"2024-03-20T23:22:58Z","timestamp":1710976978000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/229617-epstein-barr-virus-related-lymphoproliferative-disorder-in-a-patient-with-primary-myelofibrosis-a-case-report-and-literature-review"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3,20]]},"references-count":15,"URL":"https:\/\/doi.org\/10.7759\/cureus.56586","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2024,3,20]]}}}